-- Full results published in European Heart Journal Open --
-- Study met primary safety endpoint --
-- All patients alive, transplant-free, and maintained expected rate of growth one year after treatment --
-- Data supports ongoing clinical development of Lomecel-BTM for HLHS, currently being evaluated in a Phase 2a trial --